

( (S (NP-SBJ Immunex Corp.)
     (VP said
         (SBAR 0
               (S (NP-SBJ its scientists)
                  (VP isolated
                      (NP (NP a molecule)
                          (SBAR (WHNP-1 which)
                                (S (NP-SBJ *T*-1)
                                   (VP may
                                       (VP hold
                                           (NP (NP potential)
                                               (PP as
                                                   (NP (NP a treatment)
                                                       (PP for
                                                           (NP (NP disruptions)
							       (PP of
								   (NP the immune-system))
                                                               ,
							       (VP ranging
								   (PP-DIR from
									   (NP organ-transplant rejection)
									   ,)
								   (PP-DIR to
									   (NP allergies and asthma)))))))))))))))))
     .))
( (S (NP-SBJ The molecule)
     (VP is
         (NP-PRD (NP the mouse version)
                 (PP of
                     (NP (NP a protein)
                         (VP called
                             (S (NP-SBJ *)
				(NP-PRD the interleukin-4 receptor)))))))
     .))
( (S (NP-SBJ IL-4)
     (VP is
         (NP-PRD (NP a hormone)
                 (SBAR (WHNP-5 which)
                       (S (NP-SBJ *T*-5)
                          (VP directs
                              (NP (NP the growth and function)
                                  (PP of
                                      (NP (NP white blood cells)
                                          (VP involved
                                              (NP *)
                                              (PP-CLR in
						      (NP (NP the body 's)
							  immune response)))))))))))
     .))
( (S (NP-SBJ (NP The IL-4 receptor)
             (PP-LOC on
		     (NP (NP the surface)
			 (PP of
			     (NP such cells)))))
     (VP receives
         (NP (NP the hormone 's)
             message
             (S (NP-SBJ *)
                (VP to
                    (VP rally
                        (NP (NP the body 's)
                            defense))))))
     .))
( (S But
     (PP in
         (NP (NP certain conditions)
             (PP such
		 as
		 (NP (NP autoimmune diseases)
		     and
		     (NP allergies)
		     and 
		     (NP transplant rejection)))))
     ,
     (NP-SBJ-1 doctors)
     (VP would
         (VP like
             (S (NP-SBJ *-1)
                (VP to
                    (VP damp
                        (NP the immune response)
			(SBAR-PRP so
				  (S (NP-SBJ such cells)
				     (VP do n't
					 (VP touch
					     (PRT off)
					     (NP (NP harmful inflammatory reactions) or (NP cell destruction)))))))))))
     .))
( (S (S-TPC-1 (NP-SBJ (NP A soluble form)
		      (PP of
			  (NP the receptor)))
	      (VP might
		  (VP turn
		      (PRT off)
		      (NP-PRD (NP a specific part)
			      (PP of
				  (NP the immune response)))
		      (PP without
			  (NP general immune suppression)))))
     ,
     (NP-SBJ the company)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (NP-SBJ The IL-4 receptor)
     (VP is
         (NP-PRD (NP one)
                 (PP of
                     (NP (NP five such receptors)
                         (SBAR (WHNP-2 0)
			       (S (NP-SBJ-3 *T*-2)
				  (VP to
				      (VP be
					  (NP *-3)
					  (VP developed
					      and
					      tested
					      (PP by
						  (NP-LGS (NP Receptech Corp.)
							  ,
							  (NP (NP a spinoff)
							      (PP of
								  (NP Immunex)))))
					      ,
					      (PP-MNR through
						      (NP a proposed (ADJP (QP $ 30 million) *U*) initial public offering)))))))))))
     .))
( (S (NP-SBJ-1 Immunex)
     (VP will
         (VP contract
             (PP-CLR with
		     (NP the spinoff))
             (S-PRP (NP-SBJ *-1)
		    (VP to
			(VP provide
			    (NP (NP the research)
				,
				(NP development)
				and
				(NP (NP initial testing)
				    (PP of
					(NP the new agents)))))))))
     .))
( (S (NP-SBJ Immunex)
     (VP will
         (VP have
	     (NP the option
		 (S (NP-SBJ *)
		    (VP to
			(VP buy
			    (PRT back)
			    (NP Receptech shares)
			    (PP-TMP after
				    (NP five years))))))))
     .))
